Subtype
Combined Hepatocellular Carcinoma and Cholangiocarcinoma
CI-CAN-00002416Explore in graph →
3 active trials
Loading cancer entity…
Subtype
CI-CAN-00002416Explore in graph →
Clinical trials
7 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05211323 | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07243951 | Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 75 | Shanghai Zhongshan HospitalOTHER | 0 |
| Nov 24, 2025 |
| clinicaltrials |
| NCT07105748 | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)(TASK-05) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06541652 | A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers(FFCD-2205) | recruiting | — | 150 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06849180 | Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data | recruiting | — | 198 | Zhongda HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer | withdrawn | — | 0 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT02762721 | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | completed | — | 131 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 2 | Jun 8, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Aug 13, 2026source: clinicaltrials